TY  - JOUR
AU  - Beck, Michael
AU  - Blumenberg, Viktoria
AU  - Bücklein, Veit L
AU  - Bundschuh, Ralph A
AU  - Harrer, Dennis C
AU  - Hirschbühl, Klaus
AU  - Jung, Johannes
AU  - Kunz, Wolfgang G
AU  - Menhart, Karin
AU  - Winkelmann, Michael
AU  - Yakushev, Igor
AU  - Illert, Anna Lena
AU  - Eckstein, Markus
AU  - Völkl, Simon
AU  - Claus, Rainer
AU  - Hansmann, Leo
AU  - Hecker, Judith S
AU  - Kuwert, Torsten
AU  - Mackensen, Andreas
AU  - Subklewe, Marion
AU  - Hellwig, Dirk
AU  - Müller, Fabian
TI  - Liver-FDG-uptake augments early PET/CT prognostic value for CD19-targeted CAR-T cell therapy in diffuse large B cell lymphoma.
JO  - EJNMMI Research
VL  - 15
IS  - 1
SN  - 2191-219X
CY  - Heidelberg
PB  - Springer
M1  - DKFZ-2025-00672
SP  - 25
PY  - 2025
AB  - Despite revolutionary efficacy of CD19-CAR-T cell therapy (CAR-T) in aggressive B cell lymphoma, many patients still relapse mostly early. In early failure, distinct drugs support CAR-T which makes reliable and early prediction of imminent relapse/refractoriness critical. A complete metabolic remission (CR) on Fluor-18-Deoxyglucose (FDG) Positron-Emission-Computed Tomography (PET) 30 days after CAR-T (PET30) strongly predicts progression-free survival (PFS), but still fails in a relevant proportion of patients. We aimed to identify additional routine parameters in PET evaluation to enhance CAR-T response prediction.Thirty patients with aggressive B cell lymphoma treated with CAR-T were retrospectively analyzed. Pre-CAR-T, LDH was the strongest PFS-predictor also by multivariate analysis. Post-CAR-T, 10 out of 14 patients (71.4
KW  - CAR T cell therapy (Other)
KW  - DLBCL (Other)
KW  - FDG PET (Other)
KW  - Liver-SUV (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40095158
C2  - pmc:PMC11914545
DO  - DOI:10.1186/s13550-025-01201-1
UR  - https://inrepo02.dkfz.de/record/300195
ER  -